Episode Details

Hook: Peptides could rewrite medicine — but regulation, safety, and big pharma profits are shaping who gets access. This condensed version (original ~90 minutes → new ~15 minutes) of The Diary of a CEO captures Steven Bartlett’s interview with Dr. Alex Tatem on what peptides are, which therapies actually work, and why the 2023 FDA shifts tore open a gray market. Learn the science behind peptide drugs (insulin as a primer), how compounding pharmacies and patent law changed drug economics, and which compounds—BPC-157, TB500, Cerebrolysin, GLP‑1 agonists like semaglutide/tirzepatide, and emerging agents like Retatrutide—are most discussed for weight, metabolism, healing, and cognition. Dr. Alex details safety concerns, real-world results (including dramatic weight-loss and fertility improvements), and practical guidance on sourcing and clinician oversight. Topics: health and wellness, biotechnology, biohacking, personalized medicine, innovation. Listen now to get the key ideas, risks, and takeaways in minutes.